No Data
No Data
Express News | Blue Biotech: Currently, the company's stock price has increased significantly, so investors are invited to pay attention to secondary market trading risks
Blue Bio (603739): 24Q1 enzyme preparation has impressive growth rate and multiple ways to create a big animal health system
Core view In 2023, the company achieved revenue of 1,199 billion yuan, a year-on-year increase of 3.07%, net profit to mother of 81 million yuan, an increase of 15.56% over the previous year, and plans to distribute a cash dividend of 1.00 per 10 shares to all shareholders
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
The A-share synthetic biology concept continues to be strong, and Chuan Ning Biotech surged 15%
Glonghui, April 30 | Twining Biotech surged 15%. Previously, Blue Biotech broke out of the 3-row market, with Boen Group, Langkun Environmental, Fuxiang Pharmaceutical, and Jiabiyou leading gains. According to the news, recently, the Shenzhen Synthetic Biology Industry Private Equity Investment Fund Partnership (Limited Partnership) was established. The executive partner is Shenzhen Venture Capital Red Earth Private Equity Investment Fund Management (Shenzhen) Co., Ltd., with an investment amount of 1.5 billion yuan. Earlier, Tan Tianwei, an Academician of the Chinese Academy of Engineering, said that currently, under the leadership of the Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Science and Technology and other national ministries and departments are jointly developing a national action plan for biotechnology and biomanufacturing, which is expected to be introduced in the near future
Blue Biology (603739): Performance growth is in line with expectations and continues to improve the animal health system
Incidents. On April 26, 2024, the company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 1,199 billion yuan, an increase of 3.07% over the previous year; achieved net profit to mother
Changes in the synthetic biology concept drive blue biotechnology to rise and stop in a straight line
The synthetic biology concept fluctuated and increased; Azure Biotech went up and down; Shengda Biotech went up and down; Olin Biotech, Kaiser Biotech, and Bonne Group followed suit. According to the news, Tan Tianwei, an Academician of the Chinese Academy of Engineering, said at the 2024 Zhongguancun Forum annual meeting that biomantry is a new track and new business format where new quality productivity is very important. Currently, under the leadership of the Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Science and Technology, and other national ministries and departments are jointly developing a national biotechnology and biomaneling action plan, which is expected to be introduced in the near future.
No Data